Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis ($NVS) snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal. The Swiss drugmaker isn't saying much about the deal--it won't discuss the potential milestone payments that are part of the deal--but does say it plans to hustle the drug into a Phase IIb study for either diabetic neuropathy or postherpetic neuralgia, otherwise known as shingles pain. More from FierceBiotech

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.